Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against PetMed Express, Inc. for possible violations of federal securities laws and unlawful business practices [1]. Group 1: Company Announcement - On June 10, 2025, PetMed announced a delay in the release of its fourth quarter and fiscal year 2025 earnings due to the need for additional time to complete the year-end audit process [2]. - Following this announcement, PetMed's stock price dropped by $0.47 per share, or 11.22%, closing at $3.72 per share on June 11, 2025 [2]. Group 2: Legal Investigation - The law firm is reaching out to PetMed stockholders who may have suffered losses and are interested in learning more about potential claims [3]. - The firm emphasizes that there is no cost or obligation for stockholders to inquire about their rights or interests regarding these matters [3]. Group 3: Law Firm Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California, representing individual and institutional investors in various types of litigation [4].

Core Viewpoint - Bausch + Lomb Corporation is under investigation for potential violations of federal securities laws and unlawful business practices following a product recall and subsequent stock price drop [1][2]. Group 1: Product Recall and Impact - On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses from its enVista platform due to reports of toxic anterior segment syndrome (TASS), which is a complication associated with cataract surgery [2]. - The recall has raised short-term concerns regarding product safety and may lead to increased regulatory scrutiny [2]. - Following the recall announcement, Bausch + Lomb's stock price fell by $1.50 per share, representing a 10.6% decrease, closing at $15.00 on the same day [2]. Group 2: Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Bausch + Lomb on behalf of its stockholders, focusing on possible violations of federal securities laws [1]. - The law firm is reaching out to long-term stockholders who may have suffered losses or have information related to the claims [3].

Core Viewpoint - Ichor Holdings, Ltd. is under investigation for potential violations of federal securities laws and unlawful business practices following disappointing financial results in Q1 2025, which led to a significant drop in stock price [1][2]. Financial Performance - On May 5, 2025, Ichor reported its Q1 2025 financial results, missing both EPS and revenue consensus estimates [2]. - The company reported a gross margin of 12.4%, which is below the forecasted midpoint of 14.5% [2]. - Ichor attributed the margin shortfall to purchasing more external supply than anticipated, which did not translate into expected margin flow [2]. Legal Investigation - Bragar Eagel & Squire, P.C. is investigating potential claims against Ichor on behalf of stockholders who may have suffered losses [1][3]. - The investigation focuses on whether Ichor has engaged in unlawful business practices or violated federal securities laws [1].

Group 1 - Iovance Biotherapeutics reported a significant decline in first quarter 2025 product revenue, totaling $49.3 million compared to $73.7 million in the previous quarter [2] - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, indicating a reduction of over 40% at the midpoint [2] - The revenue guidance revision was attributed to recent launch dynamics of the T cell immunotherapy, Amtagvi® (lifileucel), which was launched in the U.S. in the first half of 2024 [2] Group 2 - Following the announcement of the financial results and guidance revision, Iovance's stock experienced a drop on unusually heavy trading volume [2] - Bragar Eagel & Squire, P.C. is investigating potential claims against Iovance on behalf of stockholders regarding possible violations of federal securities laws and unlawful business practices [1]

Core Viewpoint - Backblaze, Inc. is under investigation for potential violations of federal securities laws and unlawful business practices following a negative report from Morpheus Research that highlighted financial missteps and questionable accounting practices [1][2]. Group 1: Investigation and Legal Actions - Bragar Eagel & Squire, P.C. is investigating potential claims against Backblaze on behalf of its stockholders [1]. - The investigation is focused on whether Backblaze has engaged in unlawful business practices and violated federal securities laws [1]. - Stockholders who have suffered losses or have information regarding these claims are encouraged to contact the law firm [3]. Group 2: Financial Performance and Market Reaction - Backblaze's stock experienced a significant decline following the release of a critical report from Morpheus Research, which detailed alleged financial missteps since the company's IPO in November 2021 [2]. - The report accused Backblaze of questionable accounting practices, including financial manipulations and inflated forecasts [2]. - The stock price dropped during intraday trading on April 24, 2025, in response to the report [2].